{"filings":[{"id":110414,"accession_number":"0001193125-26-110720","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kestra Medical Q3 FY26 revenue $24.6M (+63% YoY); FY26 guidance raised to $93M","event_type":"earnings","confidence":"high","bullets":["Revenue of $24.6M, up 63% YoY; gross margin expanded to 52.6% from 43.4%.","Prescriptions written for ASSURE system up 58% to 5,462; driven by market share gains.","GAAP net loss widened to $34.2M vs $21.8M; adjusted EBITDA loss $21.2M vs $16.3M.","FY26 revenue guidance increased to $93M, representing 55% growth over FY25.","Cash and equivalents $291M after December 2025 equity offering of 6.9M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":66488000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127006,"accession_number":"0001193125-25-315896","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kestra Q2 FY26 revenue $22.6M (+53% YoY); guides FY26 to $91M (+52% YoY)","event_type":"earnings","confidence":"high","bullets":["Gross margin expanded to 50.6% from 39.6% YoY, driven by volume leverage and a higher mix of in-network patients.","GAAP net loss $32.8M; adjusted EBITDA loss $19.7M vs $16.1M prior year.","Prescriptions for ASSURE system grew 54% YoY to 4,696; revenue benefited from market share gains and WCD market expansion.","Raised FY26 revenue guidance to $91M (52% growth); cash $175M at Oct 31 (excl. $148M net from subsequent equity offering).","CEO cites strong commercial momentum, positive post-approval study data, and balance sheet fortification."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":41937000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127005,"accession_number":"0001193125-25-308144","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kestra Medical closes $148.4M public offering of 6.9M shares at $23.00","event_type":"other_material","confidence":"high","bullets":["Offered 6,900,000 common shares at $23.00 per share, including full exercise of underwriters' over-allotment option of 900,000 shares.","Net proceeds of approximately $148.4 million after underwriting discounts and estimated offering expenses.","Proceeds to support sales/marketing, commercialization, R&D, clinical studies, and working capital.","Underwriters included BofA Securities, Piper Sandler, J.P. Morgan, and Goldman Sachs; offering closed December 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127004,"accession_number":"0001193125-25-303104","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kestra Medical preliminary Q2 FY26 revenue up 52% YoY to $22.2-22.6M; gross margin improves to 50.0%","event_type":"earnings","confidence":"high","bullets":["Revenue expected $22.2-$22.6M vs $14.7M prior year (+52% at midpoint).","Gross profit $11.0-$11.4M (prior $5.8M); gross margin 50.0% vs 39.6%.","Loss from operations $31.6-$32.0M (prior year $19.1M), reflecting investment in growth.","Cash and equivalents ~$175M.","CEO cites commercial momentum and positive unit economics."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":41937000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127003,"accession_number":"0001193125-25-274183","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study","event_type":"other_material","confidence":"high","bullets":["21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.","Inappropriate-shock rate of 0.0065 per patient-month, below prespecified safety performance goal.","94% of patients experienced no false positive shock alarms; median wear time >23 hours per day.","2.6% of patients had at least one life-threatening VT/VF event, highlighting early risk.","Results presented as late-breaking science at AHA Scientific Sessions 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143803,"accession_number":"0000950170-25-114228","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kestra Medical Q1 FY26 revenue up 52% to $19.4M; raises FY26 guidance to $88M","event_type":"earnings","confidence":"high","bullets":["Revenue $19.4M (+52% YoY); gross margin expanded to 45.7% from 32.9%.","GAAP net loss $25.8M vs $20.3M; adjusted EBITDA loss $19.4M vs $15.7M.","4,205 prescriptions for ASSURE system, up 51% YoY; driven by new accounts and in-network mix.","FY26 revenue guidance raised to $88M, representing 47% growth over FY25.","Cash and equivalents $201.2M as of July 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":19371000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143802,"accession_number":"0000950170-25-113058","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kestra Medical shareholders elect Conor Hanley and Elizabeth Kwo as directors at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["48.8M shares voted (~95% of outstanding) at September 3, 2025 meeting.","Directors Conor Hanley and Elizabeth Kwo elected as Class I directors with ~43.1M votes each.","Ratification of PwC as independent auditor for FY 2026 passed (48.8M for, 5.4K against).","Approval of 2025 Employee Stock Purchase Plan approved (45.8M for, 975K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143801,"accession_number":"0000950170-25-095869","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kestra Medical Q4 rev $17.2M (+71%), FY rev $59.8M (+115%); guides FY26 $85M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $17.2M (+71% YoY); FY25 revenue $59.8M (+115% YoY).","Q4 gross margin 44.3% vs 13.9% prior year; FY gross margin 40.5% vs 1.3%.","Q4 prescriptions: 3,903 (+43% YoY); FY prescriptions: 13,193 (+72% YoY).","FY26 revenue guidance initiated at $85M, representing 42% growth over FY25.","GAAP net loss $51.1M in Q4; adjusted EBITDA loss $20.3M; cash $237.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162064,"accession_number":"0001193125-25-136269","cik":1877184,"company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kestra Medical adds Conor Hanley to board; amends executive employment agreements","event_type":"leadership","confidence":"high","bullets":["Conor Hanley, CEO of FIRE1, elected to Kestra board effective June 4, 2025, as Class I independent director.","Hanley previously held senior roles at ResMed and co-founded BiancaMed.","Employment agreements for CEO Brian Webster, CFO Vaseem Mahboob, and GC Traci Umberger amended.","Amendments redefine 'Good Reason' for termination, adding title demotion, relocation, compensation cuts, and change in control triggers.","No committee assignments for Hanley; standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}